REG - Trellus Health PLC - MSA Signed and Funding Update

Trellus HealthAnnouncement

Yesterday 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260327:nRSa3356Ya&default-theme=true

RNS Number : 3356Y  Trellus Health PLC  27 March 2026

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION RELATING TO TRELLUS HEALTH PLC
AND ITS SECURITIES FOR THE PURPOSES OF ARTICLE 7 OF THE MARKET ABUSE
REGULATION (596/2014/EU) AS IT FORMS PART OF THE DOMESTIC LAW OF THE UNITED
KINGDOM BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018 ("EUWA") AND AS
MODIFIED BY OR UNDER THE EUWA OR OTHER DOMESTIC LAW, INCLUDING BUT NOT LIMITED
TO THE MARKET ABUSE (AMENDMENT) (EU EXIT) REGULATIONS (SI 2019/310) ("UK
MAR").

 

 

Trellus Health plc

("Trellus Health" or the "Company")

 

MSA Signed with Leading U.S. Clinical Site Network

and

Funding Update

 

Trellus Health plc (AIM: TRLS), a healthcare company delivering Trellus
Elevate®, a digital platform that integrates data analytics with
personalised, scientifically proven resilience programmes and value-based
solutions to manage complex chronic conditions, announces that it has signed a
master services agreement ("MSA") with Gastro Health ("GH"), a leading
clinical trial site network in the United States, to partner and support trial
site performance with the use of the TrialSet™ suite of engagement tools, as
well as to co-market each other's services.

 

Whilst the MSA is not immediately revenue-generating, it further validates the
strength and differentiation of the Company's TrialSet™ offering in the
clinical trial sector and establishes a framework for future commercial
opportunities. It also enables each party access to each other's client base
through opportunities to co-market. The Company is also progressing advanced
late stage discussions regarding an additional clinical trial collaboration
and will update the market in due course.

 

Dr. Marla Dubinsky, CEO and Co-founder of Trellus Health plc said: "This MSA
with Gastro Health, alongside the recent extension of our collaboration with
J&J and the continued roll-out of TrialSet™ across multiple clinical
trials with our CRO partners, further supports the applicability of our
platform and proprietary resilience methodology across the pharmaceutical
lifecycle, from clinical development through to commercial deployment. We
remain focused on disciplined cost management while advancing commercial
discussions and converting pipeline opportunities into revenue."

The Company has continued to reduce its monthly cash burn to an average of c.
$300k as of March 2026, and expects its cash runway to extend into early April
2026. In addition, the Company is progressing discussions regarding a
potential loan from certain Directors and will update the market as
appropriate. The Convertible Facility provided by Alumni Capital LLC remains
in place, although utilisation is currently constrained by market conditions.

 

The Board remains supportive of the Company's commercial strategy and is
engaged in ongoing discussions regarding a range of potential funding options
to further extend the Company's cash runway.

 

 

Enquiries:

 

 Trellus Health plc                                                                  https://trellushealth.com/ (https://trellushealth.com/)

 Dr. Marla Dubinsky, Chief Executive Officer and Co-Founder                                 Via Walbrook PR
 Joy Bessenger, Chief Financial Officer

 Singer Capital Markets (Nominated Adviser and Broker)
 Philip Davies / James Todd / Patrick Weaver               Tel: +44 (0)20 7496 3000 303/

 Walbrook PR                 Tel: +44 (0)20 7933 8780 or trellus@walbrookpr.com
                         (mailto:trellus@walbrookpr.com)
 Lianne Applegarth /                                                           Mob: +44 (0)7584 391 303/
 Alice Woodings                                                                                                      +44 (0)7407 804 654

 

About Trellus Health plc (www.trellushealth.com (http://www.trellushealth.com)
)

 

Trellus Health® (AIM: TRLS) is a healthcare company providing value-based
innovative solutions and services, helping people with chronic conditions take
control of their health through a proven, scientifically validated
self-management solution and continuous, personalised support. Trellus
Health's approach empowers patients to better navigate the emotional and
physical challenges of their conditions, leading to significant cost savings,
enhanced treatment adherence, and long-term, sustainable health outcomes.

Trellus Health® integrates its proprietary resilience-based methodology with
the technology, tools, and expert coaching and educator team to deliver
Trellus Elevate®, a whole-person technology-enhanced condition management
platform. The Company is initially focusing on chronic costly GI conditions
that have a high mental health burden, such as Inflammatory Bowel Disease
(IBD). Among IBD patients, applying the Trellus Elevate® methodology resulted
in over 90% fewer hospitalisations and a reduction of over 70% in emergency
room visits. Given the common emotional and mental health struggles associated
with a variety of chronic conditions and therapeutic areas, Trellus Health®
considers its approach to have potential utility and demand across many
conditions.

The Company also offers Trellus TrialSet™, a solution for pharmaceutical
partners spanning clinical trials to commercialisation, applying the same
validated resilience science and platform to support trial success and
long-term patient engagement

 

The Company was founded by Icahn School of Medicine at Mount Sinai faculty
members Marla C. Dubinsky, MD, and Laurie Keefer, PhD, both world-leading
experts in treating both the physical and emotional impacts of IBD, with a
combined 50 years of pioneering whole-person healthcare innovation.

 

Shares in Trellus Health were admitted to trading on AIM in May 2021, under
the ticker TRLS. For more information, visit: www.trellushealth.com
(http://www.trellushealth.com)

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  UPDKZGZFVVDGVZM



            Copyright 2019 Regulatory News Service, all rights reserved